GlassScriptPhysician profile
Noelle V Frey
NPI 1639231509
$44,277.69
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,611 · 2020: $2,400 · 2021: $11K · 2022: $6,166 · 2023: $24.26 · 2024: $1,165 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Honoraria: $3,420 · Food and Beverage: $1,829 · Travel and Lodging: $451 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,340.00 |
| Honoraria | $3,420.00 |
| Food and Beverage | $1,829.37 |
| Travel and Lodging | $451.14 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $29,957.11 | 2019-2025 | Yescarta |
| Autolus INC | $3,637.87 | 2025 | |
| Pfizer INC. | $3,561.92 | 2022-2024 | |
| Amgen INC. | $3,245.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,372.00 | 2022 | |
| National Marrow Donor Program | $771.93 | 2024 | |
| Astellas Pharma US INC | $234.70 | 2022-2024 | Xospata |
| Celgene Corporation | $218.15 | 2022-2025 | Abecma |
| Novartis Pharmaceuticals Corporation | $131.93 | 2024 | |
| Genmab U.S., INC. | $81.59 | 2024 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Servier Pharmaceuticals LLC | $22.24 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.